



Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

September 7, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 7, 2022-- [Aldeyra Therapeutics, Inc.](https://www.aldeyra.com/) (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September:

- **Citi's 17th Annual BioPharma Conference** (1x1 meetings only)
Wednesday, September 7, 2022
Boston, Mass.
- **H.C. Wainwright 24th Annual Global Investment Conference**
Wednesday, September 14, 2022
New York, NY

Dr. Brady's presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled to begin at 10:00 a.m. ET Wednesday, September 14, 2022. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at <https://ir.aldeyra.com>. A replay will be available following the presentation and will be archived on the website for 90 days.

About Aldeyra

Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220906006042/en/): <https://www.businesswire.com/news/home/20220906006042/en/>

Investor & Media Contact:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: (857) 383-2409
ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.